Dana Investment Advisors Inc. Has $1.73 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dana Investment Advisors Inc. decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,315 shares of the medical equipment provider’s stock after selling 545 shares during the period. Dana Investment Advisors Inc.’s holdings in Lantheus were worth $1,728,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Farther Finance Advisors LLC lifted its position in Lantheus by 226.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 526 shares during the last quarter. Van ECK Associates Corp lifted its position in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Assetmark Inc. lifted its position in Lantheus by 11.4% during the 3rd quarter. Assetmark Inc. now owns 62,802 shares of the medical equipment provider’s stock worth $6,893,000 after acquiring an additional 6,442 shares during the last quarter. Atria Investments Inc acquired a new position in Lantheus during the 3rd quarter worth $330,000. Finally, Crossmark Global Holdings Inc. lifted its position in Lantheus by 11.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,935 shares of the medical equipment provider’s stock worth $542,000 after acquiring an additional 510 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 6.1 %

NASDAQ LNTH opened at $106.34 on Friday. The stock has a market cap of $7.28 billion, a P/E ratio of 17.69 and a beta of 0.44. The company’s 50-day simple moving average is $90.43 and its 200 day simple moving average is $96.80. Lantheus Holdings, Inc. has a twelve month low of $56.44 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.